Two Sigma Advisers’s Enanta Pharmaceuticals ENTA Stock Holding History

Two Sigma Advisers’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-143,300	Closed	-$2.26M	–	681
2025 Q4	$2.26M	Buy	143,300 +18,200	+15%	+$231K	﹤0.01%	1140
2025 Q3	$1.5M	Sell	125,100 -8,500	-6%	-$67.9K	﹤0.01%	1264
2025 Q2	$1.01M	Sell	133,600 -12,500	-9%	-$75.2K	﹤0.01%	1440
2025 Q1	$806K	Sell	146,100 -10,200	-7%	-$63K	﹤0.01%	1567
2024 Q4	$899K	Sell	156,300 -76,700	-33%	-$735K	﹤0.01%	1513
2024 Q3	$2.41M	Buy	233,000 +200	+0.1%	+$2.62K	0.01%	982
2024 Q2	$3.02M	Sell	232,800 -49,200	-17%	-$664K	0.01%	985
2024 Q1	$4.92M	Sell	282,000 -8,800	-3%	-$116K	0.01%	785
2023 Q4	$2.74M	Buy	290,800 +158,400	+120%	+$1.48M	0.01%	1113
2023 Q3	$1.48M	Buy	132,400 +105,900	+400%	+$1.71M	﹤0.01%	1349
2023 Q2	$567K	Sell	26,500 -9,700	-27%	-$286K	﹤0.01%	1768
2023 Q1	$1.46M	Sell	36,200 -20,400	-36%	-$974K	﹤0.01%	1440
2022 Q4	$2.63M	Buy	56,600 +9,900	+21%	+$451K	0.01%	1092
2022 Q3	$2.42M	Sell	46,700 -10,900	-19%	-$637K	0.01%	1075
2022 Q2	$2.72M	Sell	57,600 -2,400	-4%	-$130K	0.01%	1057
2022 Q1	$4.27M	Sell	60,000 -38,000	-39%	-$2.47M	0.01%	870
2021 Q4	$7.33M	Buy	98,000 +16,200	+20%	+$1.27M	0.02%	615
2021 Q3	$4.65M	Buy	81,800 +6,300	+8%	+$311K	0.01%	818
2021 Q2	$3.32M	Sell	75,500 -5,000	-6%	-$245K	0.01%	1058
2021 Q1	$3.97M	Sell	80,500 -10,300	-11%	-$514K	0.01%	947
2020 Q4	$3.82M	Buy	90,800 +11,300	+14%	+$497K	0.01%	931
2020 Q3	$3.64M	Sell	79,500 -10,900	-12%	-$528K	0.01%	882
2020 Q2	$4.54M	Sell	90,400 -1,700	-2%	-$88K	0.01%	838
2020 Q1	$4.74M	Buy	92,100 +40,000	+77%	+$2.13M	0.02%	733
2019 Q4	$3.22M	Buy	52,100 +24,600	+89%	+$1.53M	0.01%	1016
2019 Q3	$1.65M	Sell	27,500 -700	-2%	-$52K	﹤0.01%	1194
2019 Q2	$2.38M	Buy	28,200 +17,600	+166%	+$1.58M	0.01%	1137
2019 Q1	$1.01M	Hold	10,600	–	–	﹤0.01%	1523
2018 Q4	$751K	Sell	10,600 -2,800	-21%	-$215K	﹤0.01%	1613
2018 Q3	$1.15M	Sell	13,400 -34,200	-72%	-$3.43M	﹤0.01%	1461
2018 Q2	$5.52M	Buy	47,600 +5,700	+14%	+$569K	0.01%	814
2018 Q1	$3.39M	Buy	41,900 +8,800	+27%	+$677K	0.01%	1005
2017 Q4	$1.94M	Buy	33,100 +21,000	+174%	+$1.05M	0.01%	1263
2017 Q3	$566K	Buy	+12,100	New	+$486K	﹤0.01%	1709
2017 Q1	–	Sell	-8,300	Closed	-$278K	–	2373
2016 Q4	$278K	Buy	+8,300	New	+$238K	﹤0.01%	2098

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Advisers's ENTA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 143,300 shares — an estimated $2.26M sold.

Two Sigma Advisers first reported a position in ENTA in Q4 2016 and held it in 35 quarters. The position peaked at $7.33M in Q4 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

Two Sigma Advisers reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 143,300 Enanta Pharmaceuticals shares in Q1 2026, an estimated $2.26M.
Two Sigma Advisers first reported a position in Enanta Pharmaceuticals in Q4 2016 and held it in 35 quarters.
Two Sigma Advisers's Enanta Pharmaceuticals position peaked at $7.33M in Q4 2021.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.